THESIS DEFENSE — PUBLIC SEMINAR: Comparative Effectiveness and Economic Evaluation of Therapies in Advanced Non-Small-Cell Lung Cancer: a Precision Medicine Perspective

Start Date & Time: 
Wednesday, 20 July, 2016 - 10:00
End Date & Time: 
Wednesday, 20 July, 2016 - 11:00
Venue: 

Amphitheatre, Level 2, Duke-NUS

Speaker: 
Speaker Details: 

TAN PUI SAN
IBM PhD PROGRAM ( INTAKE 2012)

Synopsis: 

This thesis addressed four key knowledge gaps on the efficacy and cost-effectiveness of treatments in advanced non-small-cell lung cancer (NSCLC).1,2 Systematic synthesis of current evidence for optimal treatment strategies in the first-line and maintenance setting for advanced NSCLC was performed.1,2 Further, it elucidated precision medicine strategies to optimize treatment benefits.1,2  Finally, it evaluated the cost-effectiveness of maintenance regimens for advanced NSCLC. This thesis demonstrated clinical benefits of particular first-line with maintenance treatments and cost-effectiveness of maintenance treatments for patients with advanced NSCLC and highlighted the importance of selecting patients by clinical and/or molecular biomarkers for maximum clinical and cost-effectiveness benefits.1,2

References
1    Haaland B, Tan PS, de Castro G, Lopes G. Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations. J Thorac Oncol 2014; 9: 805–11.
2    Tan PS, Lopes G, Acharyya S, Bilger M, Haaland B. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, hi. Eur J Cancer 2015; 51: 2330–44.

 

Thesis Advisor  :  
Dr Benjamin Haaland and
Dr Marcel Bilger